Sedeprovid, a novel vitamin D based substance, plus AlphaH℗ lead to complete recovery from COVID-19 within 48 hours after application in a 7-months old baby, a 1.5-year-old toddler and three further adults

Abstract

Aim: Coronavirus Disease (COVID-19) is caused by the newly emerged coronavirus SARS-CoV-2. To prevent further spread of SARS-CoV-2 and to provide a possible prophylaxis and treatment option we report about our experience on the application of two preparations with a clinical complete recovery of five patients, including two breastfed babies, from a Coronavirus disease with severe symptoms. Material and methods: Sedeprovid (ImmunoD ® CLS ℗ ) were applied twice a day and AlphaH ℗ 20 ml concentrate was consumed once a day in the morning. The course of disease and symptoms before, during and after treatment were recorded. Results: Prior to treatment, the patients suffered from severe symptoms of confirmed COVID-19 infections, including cough, inappetence, tiredness, bone and body pain, loss of taste and smell and body temperature of ≥39ºC for several days. Within 24 hours after application of ImmunoD ® CLS ℗ and AlphaH ℗ a significant reduction of symptoms and a drop down of maximal body temperature was recorded. A complete recovery with normal body temperature and normal or close to normal activity was documented after 48 hours. No side effects were reported from the patients or the parents. Conclusion: The combination of ImmunoD ® CLS ℗ and AlphaH ℗ might offer a good treatment regimen for COVID-19 infected patients with moderate and severe disease progression before entering or after leaving the ICU ward. In addition, this protocol might be used as a prophylactic therapy option for healthcare providers. We strongly recommend the instant confirmation of these results in a controlled randomized trial for a possible rapid benefit of COVID-19 infected patients.